Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Further Empatic clinical data show improved quality of life, early responses

Oct. 24, 2008

Phase II study assesses dose titration, depression with intranasal antiobesity drug PYY-3-36

Oct. 24, 2008

LCT receives approval in New Zealand to start phase I/IIa DiabeCell study

Oct. 23, 2008

Weight loss seen with phentermine/topiramate in patients with type 2 diabetes

Oct. 23, 2008

Pfizer patents novel 5-HT2C receptor antagonists for sexual dysfunction

Oct. 23, 2008

FDA issues complete response to AMAG's NDA for ferumoxytol

Oct. 22, 2008

ACE-031 begins phase I testing for loss of muscle

Oct. 22, 2008

Non-brain-penetrant CB1 antagonists reduce weight in vivo

Oct. 22, 2008

PYY-3-36 analogue AC-163954 demonstrates improved stability, antiobesity effects in rodents

Oct. 21, 2008

Novo Nordisk reports results from LEAD phase IIIb study of liraglutide in type 2 diabetes

Oct. 21, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...